Fig. 5: Hsc70 promotes anti-tumor immunity and PD-L1 degradation in vivo.
From: Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation
A The schematic diagram of 4T1 breast cancer tumor model, created with BioRender.com, released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. B–D Tumor growth of Control (n = 12), Hsc70-WT (n = 12), and Hsc70-3KA (n = 12) group which injected indicated cells in BALB/c and BALB/c-nude mice and final tumor weights. (Х represents tumor regression during the final dissection). E, F Flow cytometry analysis of CD8+ T cells (E) and CD8+GzmB+ T cells (F) in tumors, Control (n = 12), Hsc70-WT (n = 8) and Hsc70-3KA (n = 12). G Immunohistochemistry analysis of CD8 and GzmB in the 4T1 tumors. Scale bar, 50 μm. n = 5 (each group has 5 tumor tissues, each tissue has 3 random fields). H Indicated protein levels were detected by Immunoblotting with the indicated harvested tumor cells, n = 4 (randomly selected tumor tissues from 4 mice in each group for detection) and repeated independently two times with similar results. Data represent Mean ± SEM, for B data two-way ANOVA, for (C), (E–G) data one-way ANOVA, two-sided with adjustment of Tukey’s multiple comparisons, P value is indicated in the graph. The numbers under blots represent the value (the ratio to Tubulin) of grayscale quantification. Source data are provided as a Source data file.
